Cancer and fertility: What to know after a diagnosis

Cancer therapies can affect reproductive organs, hormone signalling, and gamete production. Here is a short overview of how common treatments impact fertility.

• Chemotherapy: Some drugs—especially alkylating agents can damage eggs in the ovaries and harm sperm producing cells in the testes; risk depends on the specific regimen and total dose.
• Radiation: Pelvic or testicular radiation is particularly risky, and nearby fields can expose reproductive organs through scatter; techniques such as shielding and precise targeting may reduce exposure.
• Surgery: Surgery on reproductive organs, including the ovaries, uterus, cervix, testes, or prostate, can directly affect fertility, though fertility sparing approaches are sometimes possible.
• Hormone therapies: Medicines such as tamoxifen can delay pregnancy plans for years without directly damaging eggs. Androgen deprivation therapy for prostate cancer suppresses testosterone and sperm production.

Life stage and anatomy matter too. People with ovaries may face reduced ovarian reserve and temporary or permanent menopause, and pelvic radiation can also affect the uterus’ ability to carry a pregnancy. People with testes may have reduced sperm count or quality, which can be temporary or longer term.

Bring up fertility as early as possible—ideally at your first oncology visit—even when treatment feels urgent. Many preservation steps can start quickly and be coordinated alongside scans, blood tests, and other pretreatment tasks. For egg or embryo freezing, “random start” protocols allow ovarian stimulation to begin at almost any point in the menstrual cycle, which helps avoid long waits. If treatment must begin immediately, there are still meaningful steps you can take; if preservation isn’t possible right now, you can revisit family building later with options such as donor gametes, embryos, gestational carrier, or adoption.

Your specialist will review your diagnosis and proposed therapy to explain how each element may affect fertility, then complete a baseline assessment. For people with ovaries, this often includes ultrasound to measure antral follicle count and blood tests such as AMH; for people with testes, a semen analysis looks at sperm count, motility, and morphology. You’ll discuss preservation options, timelines, side effects, and logistics, and agree a coordination plan so preservation, if chosen, does not delay cancer treatment beyond what’s medically safe. You’ll also receive clear guidance on contraception if pregnancy is not recommended during therapy.

Fertility preservation doesn’t end when treatment begins. Ask whether fertility sparing surgery is appropriate for your case. If you’ll receive radiation, discuss shielding, adjusting fields, and techniques to minimize exposure. For chemotherapy, your oncologist may consider regimens with lower gonad toxicity when medically appropriate. Because many therapies can harm a developing fetus, reliable contraception is recommended during treatment and for a period afterward; your team will advise on methods that fit your situation. It’s also common to notice changes in libido, vaginal dryness, erectile function, or ejaculation; early attention to symptom management—such as lubricants or moisturizers, pelvic floor therapy, medications, or devices—can help you maintain comfort and intimacy.

Recovery looks different for everyone. People with ovaries may use menstrual patterns, AMH levels, and antral follicle count to get a rough picture of ovarian reserve—keeping in mind these tests don’t guarantee the ability to conceive. People with testes can reassess with semen analysis; sperm production can recover over time, and even with low counts there may be options such as surgical retrieval. The safe time to try for pregnancy is highly individual and depends on cancer type, stage, treatment, and follow-up plans; many people are advised to wait a period after chemotherapy or radiation to allow recovery and complete early surveillance. If you’re on long-term hormone therapy, your team can discuss whether and when a planned break is safe. Continue contraception if pregnancy is not advised and review all medications with your clinicians before trying to conceive.

Pregnancy after cancer is possible for many, but it requires careful coordination. Your oncology team will help determine when pregnancy is considered safe based on your history and current health. For hormone sensitive cancers, planning needs extra care; temporary interruption of certain therapies may or may not be appropriate and must be individualized. Breastfeeding after treatment can be possible, but suitability depends on your prior therapy and current medications. Personalized advice is essential—ask early so you can plan with confidence.

Family building after cancer can take many forms. Assisted reproduction using frozen eggs, embryos, or banked sperm is one path; IVF or ICSI may be recommended in some cases, and IUI can be suitable for others. Donor eggs, donor sperm, or donor embryos can expand possibilities, and a gestational carrier may be considered when pregnancy is medically contraindicated or not possible. Adoption and fostering are meaningful options for many families; processes, eligibility, and timelines differ by region, and agencies can guide requirements. Legal advice is important when using donor gametes or a gestational carrier.

Coverage for fertility and fertility‑preservation treatments varies by plan; please check your Table of Benefits or contact us to confirm what’s included.

This guide is for general information and does not replace medical advice. Decisions about fertility and cancer treatment are personal and should be made with your oncology and fertility teams. Availability, timelines, and success rates vary by diagnosis, age, treatment plan, and local resources. If pregnancy is not advised during treatment, use reliable contraception and ask your team when it’s safe to reconsider. Services and coverage vary by plan and country—please contact Allianz Partners Member Services for individualized guidance.